Clene Inc. (CLNN)
NASDAQ: CLNN · IEX Real-Time Price · USD
0.437
+0.005 (1.20%)
At close: May 1, 2024, 4:00 PM
0.415
-0.022 (-4.99%)
After-hours: May 1, 2024, 7:23 PM EDT
Clene Revenue
In the year 2023, Clene had annual revenue of $654.00K with 38.27% growth. Revenue in the quarter ending December 31, 2023 was $170.00K, a -27.35% decrease year-over-year.
Revenue (ttm)
$654.00K
Revenue Growth
+38.27%
P/S Ratio
85.82
Revenue / Employee
$7,976
Employees
82
Market Cap
56.12M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 654.00K | 181.00K | 38.27% |
Dec 31, 2022 | 473.00K | -250.00K | -34.58% |
Dec 31, 2021 | 723.00K | 517.00K | 250.97% |
Dec 31, 2020 | 206.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCLNN News
- 15 days ago - Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting - GlobeNewsWire
- 6 weeks ago - Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - GlobeNewsWire
- 7 weeks ago - Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights - GlobeNewsWire
- 2 months ago - Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024 - GlobeNewsWire
- 4 months ago - Clene says FDA finds ALS drug data not enough for accelerated nod - Reuters
- 4 months ago - Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension - GlobeNewsWire
- 4 months ago - Clene Provides Update on ALS Clinical Development Meeting With FDA - GlobeNewsWire
- 4 months ago - Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases - GlobeNewsWire